Aarey Drugs & Pharmaceuticals Ltd Share Price Today - Aarey Drugs & Pharmaceuticals Ltd Stock Price Live NSE/BSE

Aarey Drugs & Pharmaceuticals Ltd

NSE: AAREYDRUGS BSE: 524412

₹69.28

(3.48%)

Mon, 30 Mar 2026, 01:27 am

MTF 5xInvest in Aarey Drugs & Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap1.95B

PE Ratio57.39

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Aarey Drugs & Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
158.44
Net Profit
4.02
P/B
0.72
Sector P/E
39.81
P/E
23.91
EV/EBITDA
10.16
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
20.26
ROCE (Industry)
20.84
RONW (Industry)
17.81
ROE
2.96
ROCE
6.38
Debt/Equity
0.24
EPS (TTM)
1.21
Dividend Yield
0
Book Value
51.13
Interest Cover
2.31

Analysis

all

Pros

Aarey Drugs & Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Aarey Drugs & Pharmaceuticals is profitable, therefore cash runway is not a concern.
Aarey Drugs & Pharmaceuticals is profitable, therefore cash runway is not a concern.
Debt is covered by short term assets, assets are 5.7x debt.
Aarey Drugs & Pharmaceuticals's cash and other short term assets cover its long term commitments.

Cons

Unable to calculate sustainability of dividends as Aarey Drugs & Pharmaceuticals has not reported any payouts.
Unable to evaluate Aarey Drugs & Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Aarey Drugs & Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Debt is not well covered by operating cash flow (3.9%, less than 20% of total debt).
High level of physical assets or inventory.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	39.05	44.80	44.80	44.80	44.80
FII	3.86	1.13	1.97	2.34	2.34
DII	0	0	0	0	0
Public	57.09	54.07	53.23	52.86	52.86
Government	0	0	0	0	0

Technical Analysis

RSI

36.38

MACD

-2.34

50 DMA

68.05

200 DMA

72.53

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	125.31	100.02	88.37	74.73	63.08	49.44	24.15
Fibonacci	100.02	90.36	84.39	74.73	65.07	59.10	49.44
Camarilla	83.68	81.37	79.05	74.73	74.41	72.09	69.78

Pivots Level: Classic

+50.58

125.31

+25.29

100.02

+13.65

88.37

74.73

Pivot Point

LTP: 55.90

-11.64

63.08

-25.29

49.44

-50.58

24.15

Moving Average

SMAEMA

Period

Value

10-EMA
64.06
20-EMA
66.38
30-EMA
67.40
50-EMA
68.70
100-EMA
70.60
200-EMA
69.48

Announcement Date	Purpose	Action	Ex Date
11 Feb 2026	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
09 Sept 2025	agm
04 Dec 2024	egm
06 Sept 2024	agm
23 Aug 2024	agm	Annual General Meeting	24 Sept 2024
06 Dec 2023	egm
31 Jul 2023	agm
29 Jul 2023	agm	Annual General Meeting	30 Aug 2023
07 Sept 2022	agm

Aarey Drugs & Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Lupin Ltd

Divis Laboratories Ltd

Aarey Drugs & Pharmaceuticals Ltd About

Aarey Drugs & Pharmaceuticals in the manufacturing and trading of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemi'cals.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1990

Headquarters

CEO

Mihir R Ghatalia

Employees

Contact

Website

http://www.aareydrugs.com

investorgrievance@aareydrugs.com

Phone

91-22-23455543

Location

E-34 MIDC Tarapur, Boisar, Thane, Maharashtra, 401506

Year	History
1990	The company was originally incorporated as a private limited company in the name of Niharika Textiles & Chemicals Pvt. Ltd. on May 15, 1990.
1993	The Aarey group of companies took over the company and converted it into a public limited company on March 18, 1993 The company's name was changed to Aarey Drugs & Pharmaceuticals Ltd.
2008	Aarey Drugs & Pharmaceuticals Ltd appointed Mr. Chetan Kiritbhai Mehta as an Independent Director from June 02, 2008.
2012	Aarey Drugs & Pharmaceuticals Ltd issued rights in the ratio of 2:1 Aarey Drugs & Pharmaceuticals Ltd gave a bonus in the ratio of 1:5
2017	The company commenced production of Mefanamic Acid and received confirmed orders from customers until October 2017.

Client Name	Order Side	QTY	Avg Price	Date
INARAA FINANCIAL SERVICES PRIVATE LIMITED	Sell	143000	66.95	17 Feb 2026
NISHITH ATULBHAI SHAH	Buy	87127	68.95	12 Feb 2026
NISHITH ATULBHAI SHAH	Sell	258145	70.54	12 Feb 2026
SHREE SALASAR PROPERTIES & FIN.(P)LTD.	Buy	250000	70.33	12 Feb 2026
INARAA FINANCIAL SERVICES PRIVATE LIMITED	Sell	698	67	11 Feb 2026
SHREE SALASAR PROPERTIES & FIN.(P)LTD.	Buy	250000	68	11 Feb 2026
INARAA FINANCIAL SERVICES PRIVATE LIMITED	Buy	143698	66	11 Feb 2026
NISHITH ATULBHAI SHAH	Sell	534393	67	11 Feb 2026
ARCHANA PRAMOD WANI	Sell	225000	68.63	07 Jan 2026
SHREE GAUTAM ENTERPRISE PRIVATE LIMITED	Buy	175000	68.08	31 Dec 2025

Aarey Drugs & Pharmaceuticals Ltd News

Aarey Drugs Q3FY26 Revenue Drops 28% to ₹9,642.63 Lakhs

Aarey Drugs & Pharmaceuticals reported Q3FY26 revenue of ₹9,642.63 lakhs, down from ₹13,378.86 lakhs in Q3FY25. Net profit declined to ₹56.95 lakhs from ₹71.80 lakhs year-on-year.

11 Feb 2026

co actions results

Aarey Drugs Reports Q2 FY2026 Financial Results with Fixed Asset Purchases

Aarey Drugs and Pharmaceuticals Limited approved its unaudited financial results for the quarter and half year ended September 30, 2025, along with statements of assets, liabilities, and cash flow. The company purchased certain fixed assets during the reporting period that are not yet ready for intended use, with depreciation to commence once assets are fully installed and commissioned.

13 Nov 2025

earnings

Aarey Drugs & Pharmaceuticals Reports Quarterly Financial Results for June 2025

Aarey Drugs & Pharmaceuticals Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2025. The company reported total income of Rs. 1,037.60 lakhs compared to Rs. 1,288.71 lakhs in the same quarter last year. Profit for the period was Rs. 13.73 lakhs versus Rs. 12.39 lakhs in the corresponding quarter of the previous year. Basic earnings per share stood at Rs. 0.48 compared to Rs. 0.44 in the year-ago period. The company operates in a single segment of manufacturing and trading of drugs and pharmaceuticals. The results were reviewed by auditors Motilal & Associates LLP and certified by Managing Director Mihir R. Ghatalia and Chief Financial Officer Mira M. Ghatalia.

13 Aug 2025

earnings

Aarey Drugs & Pharmaceuticals Submits Revised Annual Financial Results to Correct Share Capital Error

Aarey Drugs & Pharmaceuticals Limited submitted revised audited financial results for the year ended March 31, 2025, to correct a clerical error in the paid-up share capital disclosure. The company confirmed that no other changes were made to the originally submitted results. The auditors issued an unmodified opinion on the financial results, though they noted that some plant and machinery added to fixed assets is not yet ready for use, so depreciation has not been charged. The auditors also highlighted that some debtor and creditor balances are subject to confirmation as confirmations were not available from all parties.

30 Jul 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800